Clinical trials: Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive
Non Small Cell Lung Cancer (Stage III)
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer
- Trial name
- LAURA (NCT03521154)
- Testing
- Osimertinib 80mg/40mg
- Where
- 118 sites in United States, Argentina and 15 more
- Volunteers
- 216 people
- Sponsor
- AstraZeneca
Locally Advanced or Metastatic Non-small Cell Lung Cancer With Previously Untreated EGFR-sensitive Mutations and ECOG Performance Status Score ≥2
A Clinical Study Comparing the Efficacy and Safety of Befotertinib Versus Icotinib in Patients With Previously Untreated EGFR-sensitive Mutation-positive Non-small Cell Lung Cancer With ECOG Score ≥2
This study is a multicenter, randomized, open-label, parallel-controlled clinical trial. It is designed to evaluate the efficacy and safety of Befotertinib versus Icotinib as first-line treatment in patients with previously…
- Trial name
- BEST2 (NCT07900243)
- Testing
- Befotertinib, Icotinib
- Volunteers
- 100 people
- Sponsor
- Zhou Chengzhi
Non-Small Cell Lung Cancer
A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
To assess the efficacy and safety of SH-1028 tablets versus Gefitinib, a standard of care epidermal growth factor receptor tyrosine kinase inhibitor, in patients with locally advanced or Metastatic Non Small Cell Lung Cancer
- Trial name
- NCT04239833
- Testing
- SH-1028 tablets, Gefitinib
- Volunteers
- 240 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Locally Advanced or Metastatic EGFR T790M+ NSCLC
Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours
A Phase III, Multi-Centre, Open Label, Randomized Study to Assess the Efficacy and Safety of AZD9291 in Combination with MEDI4736 versus AZD9291 Monotherapy in patients with Locally Advanced or Metastatic Epidermal Growth Factor…
- Trial name
- CAURAL (NCT02454933)
- Testing
- AZD9291, MEDI4736
- Where
- 13 sites in Canada, South Korea and 1 more
- Volunteers
- 29 people
- Sponsor
- AstraZeneca
Non-Small Cell Adenocarcinoma, Tyrosine Kinase Mutation
Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma
Treatment for patients with mutation in the epidermal growth factor receptor (EGFR) with specific domain tyrosine kinase inhibitors (TKIs) has given place to objective clinical response, increase in progression-free survival…
- Conditions
- Non-Small Cell Adenocarcinoma, Tyrosine Kinase Mutation, EGFR Gene Mutation
- Trial name
- NCT03071705
- Testing
- Metformin, TKI
- Where
- Mexico
- Volunteers
- 120 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Non Small Cell Lung Cancer
Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
Evaluate the efficacy and safety of Anlotinib plus Icotinib as the first-line treatment in patients with sensitive EGFR mutations advanced non-small cell lung cancer.
- Trial name
- ALTER-L004 (NCT03736837)
- Testing
- Anlotinib Plus Icotinib
- Where
- 5 sites in China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-small Cell Lung Cancer
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
The purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib when administered in combination with trametinib.
- Trial name
- NCT02580708
- Testing
- Rociletinib, Trametinib
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Clovis Oncology, Inc.
NSCLC Stage IIIB, NSCLC Stage IIIC
Phase 2 Study of Dacomitinib in NSCLC
This is a multi-national, multi-centre, single-arm, open-label, Phase 2 clinical study of the efficacy and safety of first-line treatment with dacomitinib, with or without dose titration, in subjects with newly diagnosed stage…
- Conditions
- NSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IV, Recurrent NSCLC
- Trial name
- NCT04027647
- Testing
- Dacomitinib
- Where
- 9 sites in Hong Kong, Malaysia and 3 more
- Volunteers
- 118 people
- Sponsor
- National Cancer Centre, Singapore
Non-Small Cell Lung Cancer
A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
To evaluate the safety and efficacy of SYS6010 combined with osimertinib as neoadjuvant therapy for patients with resectable EGFR mutation non-squamous non-small cell lung cancer.
- Trial name
- NCT07256509
- Testing
- SYS6010, Osimertinib, Pemetrexed
- Volunteers
- 120 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Leptomeningeal Metastasis
Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer
Intrathecal chemotherapy is one of the mainstay treatment options for leptomeningeal metastases. Pemetrexed is one of the first-line chemotherapeutic agents for non-squamous non-small cell lung cancer (NSCLC).
- Trial name
- NCT06304441
- Testing
- Osimertinib, Pemetrexed
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guangzhou Medical University
Non-Small Cell Lung Cancer
Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients
The main objective of this study is to evaluate the safety and tolerability of BPI-15086.
- Trial name
- NCT02914990
- Testing
- BPI-15086
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non Small Cell Lung Cancer
Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy
A multi-center, single-arm. Phase 2 exploratory trial to evaluate the efficacy and safety of HM61713 as the 1st-line anticancer agent in none-small cell lung cancer patients with EGFR mutation
- Trial name
- NCT02444819
- Testing
- HM61713
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Non Squamous Non Small Cell Lung Cancer, EGFR Positive Non-small Cell Lung Cancer
Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation
This study was designed to investigate the efficacy and safety of neoadjuvant Toripalimab (anti-PD1) plus chemotherapy for patients with resectable II-IIIB non-squamous NSCLC harboring EGFR mutation, and to explore the potential…
- Trial name
- NCT05962021
- Testing
- Toripalimab plus Chemotherapy
- Volunteers
- 126 people
- Sponsor
- Peking University People's Hospital
Non Small Cell Lung Cancer
A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
EGFR-mutated advanced NSCLC patients without ctDNA clearance after lead-in osimertinib monotherapy have inferior PFS compared with those with ctDNA clearance.
- Trial name
- NCT07375316
- Testing
- Osimertinib + Sacituzumab Tirumotecan, Osimertinib
- Where
- 4 sites in China
- Volunteers
- 120 people
- Sponsor
- Guangdong Association of Clinical Trials
Non Small Cell Lung Cancer
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of HM61713 in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine…
- Trial name
- NCT02485652
- Testing
- HM61713
- Where
- 72 sites in United States, Australia and 8 more
- Volunteers
- 162 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
To estimate parameters related to clinical outcomes in a real-world seeting, including investigator reported PFS and OS .
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms
- Trial name
- FOREFRONT (NCT06376084)
- Where
- China
- Volunteers
- 532 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer, RET Gene Mutation
The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
This is an open-label, single-arm, dose-escalation, multicenter phase I/II clinical trial. The primary endpoints of this study were to evaluated the safety, tolerability, pharmacokinetic profile and preliminary efficacy of HE003…
- Conditions
- Non Small Cell Lung Cancer, RET Gene Mutation, MET Amplification, EGF-R Positive Non-Small Cell Lung Cancer
- Trial name
- PROFILE (NCT06109558)
- Testing
- LMV-12(HE003)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Hunan Province Tumor Hospital
Non-small Cell Lung Cancer
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
The study will evaluate the efficacy and safety of treatment with chemotherapy in combination with osimertinib compared to chemotherapy in combination with placebo in patients whose disease has progressed extracranially following…
- Trial name
- COMPEL (NCT04765059)
- Testing
- Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
- Where
- 40 sites in United States, China and 4 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Non-small-lung-cell Cancer, NSCLC
Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients
This study is a randomized, multicenter clinical study ，which is designed to compare the efficacy of the safety and efficacy of treatment every 6 weeks in EGFR positive (Non-small cell lung cancer, NSCLC) with concurrent Driver…
- Conditions
- Non-small-lung-cell Cancer, NSCLC, EGFR Gene Mutation
- Trial name
- NCT04552613
- Testing
- EGFR-TKI, EGFR-TKI combined with chemotherapy (pemetrexed plus carboplatin)
- Where
- China
- Volunteers
- 114 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Non-Small Cell Lung Cancer
Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M
The primary goal is to evaluate the efficacy of osimertinib (AZD9291), in terms of the objective response rate in patients with advanced non-squamous NSCLC with EGFR mutations and the EGFR T790M mutation at diagnosis as defined…
- Trial name
- AZENT (NCT02841579)
- Testing
- Osimertinib
- Where
- 7 sites in Spain
- Volunteers
- 22 people
- Sponsor
- MedSIR